IDL Diagnostics
0.43 SEK
+8.35 %
Less than 1K followers
IDLDX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+8.35 %
+17.26 %
+0.94 %
-23.84 %
+9.74 %
+2.39 %
-22.04 %
-81.98 %
-82.04 %
IDL Diagnostics specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. IDL Diagnostics targets patient groups in different parts of the world. The head office is in Stockholm.
Read moreMarket cap
98.59M SEK
Turnover
4.86K SEK
Revenue
57.44M
EBIT %
-75.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26/2
2026
Annual report '25
All
Webcasts
Press releases
ShowingAll content types
IDL Diagnostics nomination committee for the AGM 2026
Redeye: IDL Diagnostics (Q3 Review) - Temporary headwinds in APAC
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools